PureTech Health plc

Transaction in Own Shares • Oct 11, 2023

National Storage Mechanism | Additional information

RNS Number : 6983P

PureTech Health PLC

11 October 2023

11 October 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	10 October 2023
Number of ordinary shares purchased:	13,692
Highest price paid per share:	185.80p
Lowest price paid per share:	183.00p
Volume weighted average price paid per share:	184.65p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 15,291,716 ordinary shares in treasury and has 274,176,443 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 274,176,443 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
10/10/2023	09:08:04	47	183.8	CHIX	00372960335TRLO0.1.1
10/10/2023	09:08:04	520	183.8	CHIX	00372960336TRLO0.1.1
10/10/2023	09:08:04	57	183.6	CHIX	00372960337TRLO0.1.1
10/10/2023	09:08:24	409	183.4	XLON	00372960411TRLO0.1.1
10/10/2023	09:09:31	4291	183.4	XLON	00372960626TRLO0.1.1
10/10/2023	09:09:31	381	183.2	XLON	00372960628TRLO0.1.1
10/10/2023	09:09:31	324	183.4	XLON	00372960627TRLO0.1.1
10/10/2023	09:09:32	17	183.2	AQXE	00372960629TRLO0.1.1
10/10/2023	09:09:43	21	183	AQXE	00372960672TRLO0.1.1
10/10/2023	09:09:43	190	183.2	AQXE	00372960671TRLO0.1.1
10/10/2023	09:11:49	45	183	XLON	00372960973TRLO0.1.1
10/10/2023	09:11:49	200	183.2	XLON	00372960975TRLO0.1.1
10/10/2023	09:11:49	5	183.2	XLON	00372960974TRLO0.1.1
10/10/2023	09:12:43	52	183.2	CHIX	00372961406TRLO0.1.1
10/10/2023	09:12:43	3	183.2	XLON	00372961407TRLO0.1.1
10/10/2023	09:22:02	9	184.4	XLON	00372964525TRLO0.1.1
10/10/2023	15:14:45	235	185.8	XLON	00373075547TRLO0.1.1
10/10/2023	15:14:45	387	185.8	XLON	00373075548TRLO0.1.1
10/10/2023	15:14:45	235	185.8	XLON	00373075549TRLO0.1.1
10/10/2023	15:14:45	235	185.8	XLON	00373075550TRLO0.1.1
10/10/2023	15:14:45	5429	185.8	XLON	00373075551TRLO0.1.1
10/10/2023	15:14:45	52	185.8	CHIX	00373075552TRLO0.1.1
10/10/2023	15:14:45	52	185.8	CHIX	00373075554TRLO0.1.1
10/10/2023	15:14:45	52	185.8	CHIX	00373075553TRLO0.1.1
10/10/2023	15:14:45	52	185.8	CHIX	00373075555TRLO0.1.1
10/10/2023	15:14:45	52	185.8	CHIX	00373075556TRLO0.1.1
10/10/2023	15:14:45	288	185.8	CHIX	00373075558TRLO0.1.1
10/10/2023	15:14:45	52	185.8	CHIX	00373075557TRLO0.1.1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSFLFSDIILILIV